cimetidine has been researched along with Experimental Leukemia in 2 studies
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dorr, RT | 2 |
| Alberts, DS | 1 |
| Soble, MJ | 1 |
2 other studies available for cimetidine and Experimental Leukemia
| Article | Year |
|---|---|
Cimetidine enhancement of cyclophosphamide antitumour activity.
Topics: Animals; Cimetidine; Cyclophosphamide; Drug Synergism; Drug Therapy, Combination; Guanidines; Leukem | 1982 |
H2-antagonists and carmustine.
Topics: Animals; Bone Marrow; Carmustine; Cimetidine; Drug Synergism; Histamine H2 Antagonists; Leukemia P38 | 1989 |